Premium
C‐terminal pentapeptide of osteogenic growth peptide regulates hematopoiesis in early stage
Author(s) -
Hui Zhong,
Yu Liu,
Xiaoli Yang,
Xiang He,
Fan Zhao,
Ningbo Hou,
Zhigang Yuan,
Ping Li,
Yanhong Zhang,
Qingjun Ma
Publication year - 2007
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.21258
Subject(s) - haematopoiesis , stem cell , bone marrow , biology , cd34 , stem cell factor , microbiology and biotechnology , progenitor cell , hematopoietic stem cell , immunology , andrology , medicine
Osteogenic growth peptide (OGP) was characterized in regenerating bone marrow, which can increase osteogenesis and hematopoiesis. The carboxy‐terminal pentapeptide is a naturally occurring human and murine mitogen equipotent to OGP. In this study, we evaluated the potential role of OGP10–14 in regulation of hematopoiesis in human hematopoietic stem cells and animal model. Our results showed CD34+ stem cells from umbilical cord blood (UBC) were significantly increased in OGP10–14 treated samples, which is nearly equivalent to the results obtained from the combinations of IL3, IL11, G‐CSF, and EPO group. OGP10–14 can also stimulate the differentiation of stem cells from bone marrow at the level of noncommitted progenitor stem cells, thus increasing the number of reconstituted red and white cells as well as platelets after injected i.m. everyday continuing for 5 days in hematopoietic function damage mice comparing with the OGP‐untreated group. These data implicate that the role of OGP10–14 regulating hematopoiesis is in the early stage of the whole hematopoietic growth factors (HGFs) regulating network, just like the position of interleukin 13 in the hematopoiesis network. J. Cell. Biochem. 101: 1423–1429, 2007. © 2007 Wiley‐Liss, Inc.